Atlas Trials

Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer

Clinical trial NCT06759090 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06759090
Sponsor
Zhejiang University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Pancreatic Carcinoma
Start date
2025-01-15
Primary completion
2027-01-15
Enrollment
43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.